文献速递血液净化与透析

前瞻性随机多中心临床研究:自膨式覆膜支架与经皮腔内血管成形术治疗上肢血液透析动静脉内瘘狭窄的比较

Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis.
PubMed 文献 · Kidney Int · 2023-03-27

该前瞻性随机多中心研究将接受经皮腔内血管成形术(PTA)后的覆膜支架与单纯PTA用于治疗上肢血液透析动静脉内瘘(AVF)狭窄进行比较。142例患者随机分配至覆膜支架组,138例分配至单纯PTA组。结果显示覆膜支架组安全性非劣效,6个月和12个月靶病变一期通畅率(TLPP)均优于单纯PTA组,24个月时覆膜支架组TLPP更优、靶病变再干预次数更少且再干预间期更长。

要点

  • 覆膜支架组6个月TLPP为78.7%,单纯PTA组为55.8%,覆膜支架组更优。
  • 覆膜支架组12个月TLPP为47.9%,单纯PTA组为21.2%,覆膜支架组更优。
  • 24个月时覆膜支架组TLPP优于单纯PTA组28.4%,靶病变再干预次数更少。

核心结论

  • 在多中心前瞻性随机研究中,治疗AVF狭窄时使用覆膜支架相比单纯PTA显示非劣效安全性,并在24个月内具有更好的TLPP和更少的靶病变再干预。

研究设计与样本

  • 前瞻性、随机、多中心临床研究,纳入AVF狭窄≥50%且存在AVF功能障碍证据的上肢血液透析患者。
  • 患者接受PTA后随机分配至覆膜支架组142例或单纯PTA组138例。
  • 主要结局为30天安全性(非劣效检验)和6个月靶病变一期通畅率(TLPP,优效性检验)。
  • 还假设检验了12个月TLPP和6个月通路回路一期通畅率(ACPP),并观察额外临床结局至2年。

主要发现

  • 安全性显著非劣效。
  • 6个月TLPP覆膜支架组为78.7%,单纯PTA组为55.8%,覆膜支架组更优。
  • 12个月TLPP覆膜支架组为47.9%,单纯PTA组为21.2%,覆膜支架组更优。
  • 6个月ACPP两组间无统计学差异。
  • 24个月时观察到有利于覆膜支架组的差异:TLPP优于单纯PTA组28.4%,靶病变再干预次数更少(1.6 ± 1.6 vs 2.8 ± 2.0),靶病变再干预间期更长(380.4 ± 249.5天 vs 217.6 ± 158.4天)。

关键数值与推荐

  • AVF狭窄程度≥50%且存在AVF功能障碍证据为纳入条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Use of a covered stent after percutaneous transluminal angioplasty (PTA) was compared to PTA alone for treatment of upper extremity hemodialysis patients with arteriovenous fistula (AVF) stenoses. Patients with AVF stenosis of 50% or more and evidence of AVF dysfunction underwent treatment with PTA followed by randomization of 142 patients to include a covered stent or 138 patients with PTA alone. Primary outcomes were 30-day safety, powered for noninferiority, and six-month target lesion primary patency (TLPP), powered to test whether TLPP after covered-stent placement was superior to PTA alone. Twelve-month TLPP and six-month access circuit primary patency (ACPP) were also hypothesis tested while additional clinical outcomes were observed through two years. Safety was significantly non-inferior while six- and 12-month TLPP were each superior for the covered stent group compared to PTA alone (six months: 78.7% versus 55.8%; 12 months: 47.9% versus 21.2%, respectively). ACPP was not statistically different between groups at six-months. Observed differences at 24 months favored the covered-stent group: 28.4% better TLPP, fewer target-lesion reinterventions (1.6 ± 1.6 versus 2.8 ± 2.0), and a longer mean time between target-lesion reinterventions (380.4 ± 249.5 versus 217.6 ± 158.4 days). Thus, our multicenter, prospective, randomized study of a covered stent used to treat AVF stenosis demonstrated noninferior safety with better TLPP and fewer target-lesion reinterventions than PTA alone through 24 months.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Dolmatch B, Cabrera T, Pergola P, et al. Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis. Kidney Int. 2023. PMID: 36990214. doi:10.1016/j.kint.2023.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。